Agilent’s second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase in digital orders, and pointed to operational changes—including the Ignite transformation initiative—that drove early wins in pricing and procurement. While most end markets performed as expected, academia and government remained soft, and management described the macroeconomic and geopolitical environment as “highly dynamic,” underscoring ongoing uncertainty.
Is now the time to buy A? Find out in our full research report (it’s free).
Agilent (A) Q1 CY2025 Highlights:
- Revenue: $1.67 billion vs analyst estimates of $1.62 billion (6% year-on-year growth, 2.7% beat)
- Adjusted EPS: $1.31 vs analyst estimates of $1.26 (3.6% beat)
- The company slightly lifted its revenue guidance for the full year to $6.77 billion at the midpoint from $6.72 billion
- Management reiterated its full-year Adjusted EPS guidance of $5.58 at the midpoint
- Operating Margin: 18%, down from 23.1% in the same quarter last year
- Organic Revenue rose 5% year on year (-7.6% in the same quarter last year)
- Market Capitalization: $32.99 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Agilent’s Q1 Earnings Call
- Patrick Donnelly (Citi) inquired about order trends and possible pull-forwards tied to tariffs. Management replied that while consumables saw some order acceleration in China due to tariff concerns, overall business remained stable and no material impact was expected for future quarters.
- Jack Meehan (Nephron Research) asked for clarification on the impact of China tariff-related order timing and how it would affect group-level growth rates. CFO Bob McMahon explained that consumables revenue was pulled forward but would be offset by normalized instrument deliveries in upcoming quarters.
- Rachel Vatnsdal (JPMorgan) questioned the timing and magnitude of any potential tailwinds from pharmaceutical manufacturing reshoring. CEO Padraig McDonnell indicated that such trends were in early stages and would not meaningfully impact results for at least two to three years.
- Puneet Souda (Leerink Partners) requested details on the replacement cycle for the Infinity III LC system in various lab settings. Management described strong adoption and a growing sales funnel, but noted that full replacement cycles typically play out over six to nine months per customer.
- Vijay Kumar (Evercore ISI) probed the drivers behind sequential margin trends and the impact of Ignite-related restructuring costs. McMahon clarified that margin improvement in the second half would come from volume leverage and organizational savings, with most restructuring charges reflected in GAAP, not adjusted results.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will watch for (1) sustained momentum in PFAS testing and CDMO segment order growth, (2) evidence that Ignite-driven cost savings and pricing actions are offsetting tariff impacts and supporting margin stability, and (3) the pace of customer adoption for new instruments like the Infinity III LC system. Progress in these areas will be key to tracking Agilent’s ability to navigate external headwinds and deliver on its operational commitments.
Agilent currently trades at $116.13, up from $110.88 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
